Grifols avanza en la detección precoz del Parkinson con una plataforma capaz de identificar señales hasta 12 años antes del diagnóstico - Corresponsables Grifols avanza en la detección precoz del Parkinson con una plataforma capaz de identificar señales hasta 12 años antes

🧠 #Grifols logra detectar señales del #Parkinson hasta 12 años antes

🔬 IA + proteómica + datos reales impulsan el avance

🔗 Toda la información de su estudio piloto de Chronos-PD, ya en #Corresponsables 👉 www.corresponsables.com/actualidad/g...

¿Debe Grifols recomprar acciones para frenar bajistas? Grifols afronta la presión de sus minoritarios para recomprar acciones mientras los bajistas aprietan y los grandes fondos redoblan su apuesta Grifols vive uno de esos momentos en los que la Bolsa deja de ser un termómetro y se convierte en un ring. La presión de los accionistas minoritarios para que el consejo apruebe una […]

¿Debe Grifols recomprar acciones para frenar bajistas? #Grifols #Bolsa #IBEX35 #Acciones #Mercados #Inversion #FondosDeInversion #Bajistas #Economia #Empresas #Finanzas #Resultados #felizjueves #9deabril donporque.com/grifols-reco...

Grifols board backs IPO for US business Spanish plasma medicine specialist Grifols is planning to sell a minority stake in its US business, via an IPO, to help pay down its debt

Spanish #plasma medicine specialist #Grifols is planning to sell a minority stake in its US business, via an IPO, to help pay down its debt.
pharmaphorum.com/news/grifols...

¿Por qué sube la Bolsa y Grifols se dispara un 8%? El Ibex rebota por encima de 17.100 puntos y Grifols se dispara tras su giro en EE UU, con petróleo a la baja y alivio en las Bolsas europeas La Bolsa española ha encontrado este miércoles una rendija...

¿Por qué sube la Bolsa y Grifols se dispara un 8%? #Ibex35 #BolsaEspañola #Grifols #Mercados #MercadosFinancieros #Economia #Inversion #Bolsa #Petroleo #BCE #BBVA #IAG #ArcelorMittal #felizmiercoles #25demarzo donporque.com/sube-la-bols...

Grifols Weighs IPO of US Biopharma Unit Grifols is considering an IPO for its US biopharma unit (Seeking Alpha, Mar 24, 2026); analysts cite a potential $4–8bn valuation and US plasma supplies ~60–70% of global collections.

Grifols Weighs IPO of US Biopharma Unit: Grifols is considering an IPO for its US biopharma unit (Seeking Alpha, Mar 24, 2026); analysts cite a potential $4–8bn valuation and US plasma supplies ~60–70% of global collections. 👈 Read full analysis #Grifols #IPO #Biopharma #Investing #Healthcare

DO NOT GO TO FOR PROFIT PLASMA CLINICS! Here in Alberta, #Grifols’ Plasma Centre in Calgary received a non-compliant rating December 2025, meaning its activities do not comply with the Food and Drugs Act and Blood Regulations. Other CDN Grifols have also experienced non-compliant ratings. #ForProfit

Una rama de los Grifols rehabilita un antiguo edificio industrial del 22@ de Barcelona Ponder Trade redobla su apuesta por el desarrollo urbano. Se trata del family office de una de los Grifols Coma-Cros, una de las ramas de los fundadores de Grifols, que este jueves...

#Barcelona | Una branca de la família #Grifols rehabilita un antic edifici industrial situat al #22@ que sobresurt per les solucions de #sostenibilitat que incorpora via EXPANSIÓN www.expansion.com/catalunya/20...

¿Qué ha cambiado en Grifols para ganar 402 millones? Grifols cierra 2025 con 402 millones de beneficio, más caja y menos deuda: claves del salto, negocio del plasma y objetivos para 2026 y foco. Grifols cerró 2025 con un beneficio neto de 402 millones d...

¿Qué ha cambiado en Grifols para ganar 402 millones? #Grifols #Bolsa #Ibex35 #ResultadosEmpresariales #BeneficioNeto #Deuda #EBITDA #FlujoDeCaja #Salud #IndustriaFarmaceutica #Plasma #Economia #27defebrero #felizviernes donporque.com/grifols-gana...

📈 Grifols mejora su calificación a B1 con perspectiva estable según Moody's. Un reflejo de su solidez financiera y liderazgo en la biotecnología. 🚀 #Grifols #Moody's #CalificaciónCrediticia #Biotecnología #CrecimientoSostenible

The #BioRegionReport is supported by
#Alira Health, @astrazeneca.bsky.social sky.social, #Johnson&Johnson, #Roche, #Sanofi, #Almirall, @amgen.bsky.social y.social, #Bayer, @cuatrecasas.bsky.social, #Esteve, #Grifols, #Menarini, #Hipra, #Pfizer

Original post on cincodias.elpais.com

Moody’s eleva el rating de Grifols a B1 por la mejora de los ingresos y la rentabilidad La farmacéutica, que ya trabaja en la refinanciación de su deuda, mejora las relaciones con las agencias ...

#Empresas #Grifols #Laboratorios #Moody's #Deuda […]

[Original post on cincodias.elpais.com]

🔊 Listen Now: Some say selling plasma is exploitative — others say it's a life-saving economy booster All Things Considered on NPR One | 4:06

#BloodMoney

#poor?
#choices?

Sell your #BloodPlasma
Fall prey to #PredatoryLending
Turn to #crime
or suffer and die.

#Grifols feeds on #American #Poverty.

We are a very cruel society.

"Some say selling plasma is exploitative — others say it's a life-saving economy booster."

Grifols obtiene la aprobación de la FDA para su nuevo concentrado de fibrinógeno - Corresponsables Grifols obtiene la aprobación de la FDA para FESILTY™, su nuevo concentrado de fibrinógeno para tratar episodios agudos de sangrado en pacientes con deficiencia congénita

💙 #Grifols recibe la aprobación de la FDA 🇺🇸 para FESILTY™, su nuevo concentrado de fibrinógeno para episodios agudos de sangrado en pacientes con deficiencia congénita

Disponible en EE. UU. en 2026 👉 www.corresponsables.com/actualidad/g...

🔝 La inversión #inmobiliaria apunta a nuevo récord

🤔 #Grifols abordará la recompra de los centros de #scranton en 2026

🛑💶Los bancos frenan los créditos a #renovables por la incertidumbre que afronta el sector

🗞️temas en las #portadas de la prensa económica 👇

FDA expands Grifols’ antithrombin therapy in children The US regulator approves expanded Thrombate III label, offering new treatment options for children with hereditary antithrombin deficiency.

FDA approves expanded use of Grifols’ THROMBATE III, now the only antithrombin concentrate authorized for both adults and children with hereditary antithrombin deficiency.
#News #HealthcareNews #Pediatrics #FDAApproval #RareDisease #Thrombosis #Grifols

FDA expands Grifols’ antithrombin therapy in children The US regulator approves expanded Thrombate III label, offering new treatment options for children with hereditary antithrombin deficiency.

FDA approves expanded use of Grifols’ THROMBATE III, now the only antithrombin concentrate authorized for both adults and children with hereditary antithrombin deficiency.
#News #HealthcareNews #Pediatrics #FDAApproval #RareDisease #Thrombosis #Grifols

Grifols celebra la revisión positiva de su perspectiva por Fitch Ratings y mantiene su calificación “B+”.

Reflejo de su apuesta por innovación, disciplina financiera y sostenibilidad 👉 miniurl.cl/oo00yr

#Grifols #FitchRatings #RSE

Grifols alcanza la categoría Platino en la calificación de Sostenibilidad de EcoVadis - Corresponsables Grifols obtiene la categoría Platino en EcoVadis, situándose en el top 1% mundial por su excelencia en Sostenibilidad y desempeño ESG

🏆 #Grifols logra la categoría Platino en #EcoVadis, situándose en el top 1% de compañías por su desempeño en #Sostenibilidad y #ESG 🌱

🔎 Más info en #Corresponsables 👉 www.corresponsables.com/actualidad/g...

Grifols expands US diagnostic manufacturing with new San Diego facility The company plans to open a high-tech San Diego plant to boost US blood typing production, meeting rising transfusion demand.

Grifols plans to open a high-tech San Diego plant to boost US blood typing production, meeting rising transfusion demand.

#News #USAmanufacturing #manufacturing #onshoring #USA #Grifols #BloodTransusion

Grifols expands US diagnostic manufacturing with new San Diego facility The company plans to open a high-tech San Diego plant to boost US blood typing production, meeting rising transfusion demand.

Grifols plans to open a high-tech San Diego plant to boost US blood typing production, meeting rising transfusion demand.

#News #USAmanufacturing #manufacturing #onshoring #USA #Grifols #BloodTransusion

I had a wonderful time at #Grifols pharmaceutical company yesterday taking a tour and seeing how my medicine gets made, then I got to participate in a panel discussion so the staff there could hear how the medication has impacted my life.... 1/3

Just returned from an inspiring meeting in Cairo!

Grateful for the thoughtful contributions of Dr. @NesrinEradwan, Dr. Sohilla Lofty, Prof. Aisha El-Marsafy, Dr. Nermine Gamal & all + 🙏 to our NMO rep Ms. Shaimaa El Araby.

Thank you all for your insights & to #Grifols for the support!

GRIFOLS ROBARÀ EL NADAL ALS NENS DE PARETS DEL VALLÈS? A l’empresa farmacèutica GRIFOLS se li ha posat al cap l’obsessió de fer-nos treballar els dies festius de Nadal, quan tradicionalment havia respectat aquest període de conciliació, retrobada famil…

L'empresa #GRIFOLS pretén robar el #Nadal al nens i nenes de #ParetsDelVallès #MolletDelVallès #Granollers (...) #VallèsOriental
cgtcatalunya.cat/cgtvallesori...

Grifols avanza +3% antes de su Junta de Accionistas. Los fondos activistas, que presionaban cambios en el consejo, parecen firmar tregua para conservar influencia en las votaciones clave. #Grifols #Accionistas #Mercados (1/2)

US court finds enough evidence to proceed with Grifols lawsuit against Gotham City MADRID (Reuters) -A New York court found enough evidence to continue with the defamation lawsuit filed by Spanish pharmaceutical company Grifols (BME:GRLS) against short seller Gotham City Research, Grifols said in a statement on Friday. Based on its findings, the Federal District Court for the Southern District of New York rejected a request filed by Gotham City to dismiss the lawsuit, Grifols said. In January 2024, Gotham, which had previously shorted Grifols shares, released a report accusing the company of overstating earnings and understating debt. Grifols denied the allegations but lost around a third of its market value following the report. Shorting involves borrowing shares in order to sell them, with the hope of buying them back more cheaply to make a profit. According to Grifols, the court also found that Grifols adequately argued that Gotham City’s report contained false statements, such as that the company had failed to disclose a $95 million loan to Scranton Enterprises. Gotham City did not immediately respond to a request for comment.

Click Subscribe #Grifols #GothamCity #Lawsuit #Court #LegalNews

Grifols’ rating upgraded to B2 by Moody’s with positive outlook Investing.com -- Moody’s Ratings has announced an upgrade in Grifols (BME:GRLS) S.A.’s corporate family rating (CFR) and probability of default rating (PDR) from B3 to B2. The instrument ratings of the backed senior secured instruments issued by Grifols, Grifols World Wide Operations Ltd., and Grifols World Wide Operations USA, Inc. have also been upgraded from B2 to B1. Additionally, the instrument ratings of the backed senior unsecured instruments issued by Grifols Escrow Issuer, S.A.U. have been upgraded from Caa2 to Caa1. The outlook for all entities remains positive. The upgrade is a reflection of Grifols’ strong operating performance, robust revenue, and profitability growth, and improved management execution, which has led to an improvement of its key credit metrics. Moody’s expects Grifols’ gross leverage to trend below 6.5x by the end of 2025 from 7x for the last twelve months to March 2025, and its EBITDA to interest expense to be around 3x in 2025. The company’s free cash flow (FCF) is forecasted to be about €250-270 million over the next 12-18 months and continued good liquidity. The positive outlook is based on expectations that Grifols’s operating performance and credit metrics will continue to improve over the next 12-18 months. Specifically, its gross leverage is forecasted to trend towards 5.5x, with an EBITDA to interest expense above 3x, and increasing cash generation. The B2 rating also reflects Grifols’ strong market position, scale, and vertical integration in human blood plasma-derived products, which are relevant for the industry. The rating also considers the company’s current high leverage, high capital intensity of the business, and working capital requirements which can have large swings during the fiscal year, and are important drivers of FCF. Grifols’ liquidity is seen as good, supported by €753 million of cash balances at the end of March 2025, and a fully available revolving credit facility (RCF) of $938 million due in May 2027. The company’s next debt maturities are about €3 billion due in 2027. The rating could be upgraded if there is a continued improvement to operating, financial performance, profitability, and cash flow generation. However, the rating could be stabilized if the expected gradual improvement of key credit metrics does not materialize over the next 12-18 months. Conversely, the rating could be downgraded if Grifols’ operating performance weakens, leading to a worsening of credit metrics. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Click Subscribe #Grifols #Moodys #RatingUpgrade #B2Rating #FinanceNews

ISBT Corporate Partner Webinar: Sickle Cell and Transfusion: Bridging the Gap in Patient Care

Join us 30 April 2025, 3:00 PM – 4:00 PM CEST for a free webinar by Grifols. Learn about transfusion challenges in sickle cell disease, and strategies for managing post-transfusion hemolysis.

www.isbtweb.org/events/isbt-...

#SickleCell #Transfusion #ISBT #Grifols #FreeWebinar

Original post on cincodias.elpais.com

Barclays respalda a Grifols: “Puede ser un ganador en la crisis de los aranceles” El banco cr...

cincodias.elpais.com/companias/2025-04-11/bar...

#Empresas #Grifols […]

[Original post on cincodias.elpais.com]

📈 Grifols salta un 13% por rumores de nueva OPA

Las acciones de Grifols suben un 13% ante rumores de que Brookfield ha reactivado conversaciones para una nueva OPA. Esta vez la valoración rondaría los 7.000M€, un 4,4% más que la anterior. ¿Será suficiente? #Grifols (1/3)

Grifols soars 11% on report of Brookfield resuming takeover negotiations Investing.com -- Grifols (BME:GRLS) shares surged more than 11% on Wednesday following a report by El Confidencial that Canadian investment firm Brookfield has renewed takeover discussions with the Spanish pharmaceutical group. The stock traded at 9.06 euros as of 08:19 GMT. According to the report, Brookfield has reached out to the Grifols founding family and is weighing a new offer that could value the company at around 7 billion euros ($7.55 billion). The fund is reportedly working with Morgan Stanley on the potential bid. Brookfield had previously made a non-binding proposal last November, valuing Grifols at 6.7 billion euros, but withdrew after the company’s leadership dismissed the offer as inadequate and advised shareholders not to sell. After Capital Markets Day (CMD), Grifols “is in a superior cash and governance position and on track to realise strong growth,” Barclays analysts said. The analysts believe that a potential take-private of Grifols could allow the new management team, in place since 2024, to focus more effectively on advancing the company’s turnaround strategy launched in September 2022. They argue that operating outside the pressures of public market volatility would benefit the process. At the time of Brookfield’s previous bid, Barclays had suggested a fair value for Grifols A shares in the range of €12 to €13, higher than the €10.5 per share offer that was rejected. The investment bank also pointed out that the proposal had not accounted for the company’s requirement to offer the same price for both A (ordinary) and B (preferred) shares under its articles of association. Barclays noted that investor feedback then indicated some shareholders were seeking up to €15 per share. “We expect shares to react positively to the news that the long-term GRF value could be realised near-term, but warn against the return of media headline risk as we predict a return of articles focused on the potential progress of a deal,” analysts concluded.

Click Subscribe #Grifols #Brookfield #Takeover #Investing #StockMarket